Axsome Therapeutics, Inc.
NASDAQ:AXSMBiotechnology
+$0.25 today
- Market cap
- $7.05B
- Beta
- 0.60
- P/E (TTM)
- -68.6
- EPS (TTM)
- -$3.68
Volume 0.74M
Average 0.72M
AXSM Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Axsome Therapeutics, Inc.NASDAQ: AXSM
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development declines year over year
Q2 FY2026 research & development of $46.23M fell 6.7% year over year, behind the -3.5% change in trailing-twelve-month research & development. Sequentially, it fell 12.2% from the prior quarter. Over 3 fiscal years it compounded at +46.8% a year.
Context
- Research & development amounted to 28.7% of revenue in FY2025, down 19.8 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -6.7% toward the trailing-twelve-month pace of -3.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 183.28M USD
- Year-over-year change
- -2.0%
- 4-year CAGR
- +33.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 183.28M | -2.0% |
| FY2024 | 2024-12-31 | 187.08M | +91.0% |
| FY2023 | 2023-12-31 | 97.94M | +69.0% |
| FY2022 | 2022-12-31 | 57.95M | -0.2% |
| FY2021 | 2021-12-31 | 58.06M | — |
Research & Development vs competitors
How AXSM compares with its peers on the latest reported figures
- AXSM's LTM Jun 2026 research & development of $187.86M is the 6th highest of the 11 companies compared; the peer median is $229.46M.
- Its year-over-year change of -3.5% is the 7th highest of 11, against a peer median of +17.9%.
- Research & development amounts to 24.2% of revenue for AXSM, versus a peer median of 33.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.23B | +30.7% | +29.9% | 33.3% | |
| LTM Sep 2026 | $623.61M | -26.8% | +9.9% | 13.2% | |
| LTM Jun 2026 | $400.72M | -3.9% | +5.3% | 11118.8% | |
| LTM Sep 2026 | $371.08M | +36.1% | +41.7% | — | |
| LTM Sep 2026 | $289.11M | +17.6% | +19.9% | — | |
| LTM Jun 2026 | $187.86M | -3.5% | +46.8% | 24.2% | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $169.81M | +60.3% | +48.2% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M | -21.6% | +18.9% | — |
| LTM Jun 2026 | $126.09M | +18.1% | +12.5% | 15.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.93M | +58.7% | +118.3% | 539.7% |
| LTM Dec 2025 | $31.8M | -27.0% | -0.3% | — | |
| Peer median (excluding AXSM) | $229.46M | +17.9% | +19.4% | 33.3% | |
Competitors are the stored peer set for AXSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 50.04M | 270.6M | 385.69M | 638.5M |
| Cost of Revenue | 0 | 5.2M | 26.07M | 33.3M | 47.48M |
| Gross Profit | 0 | 44.84M | 244.54M | 352.39M | 591.02M |
| Gross Margin | — | 89.6% | 90.4% | 91.4% | 92.6% |
| Research & Development | 58.06M | 57.95M | 97.94M | 187.08M | 183.28M |
| Selling, General & Admin | 66.65M | 159.25M | 323.12M | 411.36M | 570.6M |
| Operating Expenses | 124.71M | 224.64M | 476.36M | 632.95M | 760.25M |
| Depreciation & Amortization | 76K | 4.4M | 6.83M | 7.96M | 9.06M |
| EBITDA | (124.63M) | (175.4M) | (224.99M) | (272.6M) | (168.08M) |
| EBITDA Margin | — | -350.5% | -83.1% | -70.7% | -26.3% |
| Operating Income | (124.71M) | (179.8M) | (231.83M) | (280.56M) | (169.24M) |
| Operating Margin | — | -359.3% | -85.7% | -72.7% | -26.5% |
| Interest Income | 0 | 0 | 0 | 0 | 9.37M |
| Interest Expense | 5.7M | 7.34M | 6.45M | 6.57M | 6.56M |
| Other Income / Expenses | (5.7M) | (7.34M) | (6.45M) | (6.57M) | (14.47M) |
| Income Before Tax | (130.4M) | (187.13M) | (238.28M) | (287.13M) | (183.7M) |
| Pre-Tax Margin | — | -374.0% | -88.1% | -74.4% | -28.8% |
| Income Tax Expense | 0 | 0 | 960K | 85K | (530K) |
| Net Income | (130.4M) | (187.13M) | (239.24M) | (287.22M) | (183.17M) |
| Net Margin | — | -374.0% | -88.4% | -74.5% | -28.7% |
| EPS (Basic) | (3.47) | (4.60) | (5.27) | (5.99) | (3.68) |
| EPS (Diluted) | (3.47) | (4.60) | (5.27) | (5.99) | (3.68) |
| Weighted Avg Shares | 37.62M | 40.66M | 45.43M | 47.91M | 49.75M |
| Weighted Avg Shares (Diluted) | 37.62M | 40.66M | 45.43M | 47.91M | 49.75M |
Axsome Therapeutics, Inc.
NASDAQ:AXSM
Intrinsic Alpha fair value
Locked
Current Price
$134.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.